Clinical Trial Update: Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

View source ↗

Summary

This completed observational study evaluated health-related quality of life, symptom severity, and pain in patients with PIK3CA-related Overgrowth Spectrum.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca-related Overgrowth Spectrum

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: PIK3CA-related Overgrowth Spectrum | Status: COMPLETED